[Alteration of VHL gene in patients with metastatic renal cell carcinoma].
Blocks of preparations from 22 patients with metastatic renal cell carcinoma on target therapy were studied. The patients were examined for mutations/methylation of VHL gene. The mutations were detected in 10 (45.5%) of 22 patients, VHL methylation was found in 1 (4.5%) patient. Overall survival was 36.4 and 66.7% in the groups of patients with and without gene VHL alteration, respectively. Progression-free survival was 47.6 and 57.1%, respectively (p = 0.619), relapse-free survival--63.6 and 45.5%, respectively (p = 0.682), progression was registered in 36.4 and 54.5%, respectively (p = 0.682). Gene VHL inactivation had no effect on prognosis of the disease and results of anti-angiogenic therapy.
M V
MV
Peters
V B
VB
Matveev
M I
MI
Volkova
S A
SA
Kalinin
D M
DM
Mikhaĭlenko
D020533:Angiogenesis Inhibitors; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy; D019175:DNA Methylation; D018572:Disease-Free Survival; D005260:Female; D020868:Gene Silencing; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D009154:Mutation; D009362:Neoplasm Metastasis; D015996:Survival Rate; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human